Cases
Representative Matters: Life Sciences
Medical Technologies: Represented Medical Outcomes Research Analytics in its merger with Helix Technologies, Inc., a publicly traded company that provides software to the cannabis industry,
the successor entity in connection with its registration as a public company.
Represented a leading global financial institution in its investment in a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines.
Represented a leading global financial institution in its investment in a biopharmaceutical company specializing in heart disease treatment.
Represented Tissue Analytics, a developer of automated mobile wound
skin imaging
predictive analytics solutions, in its sale to Net Health, a provider of cloud-based Electronic Health Record (EHR) software for specialized care settings
a portfolio company of The Carlyle Group, Level Equity
Silversmith Capital Partners.
Represented Texas Hospice Holdings, LLC, a multi-state hospice facility operator, in connection with the sale of all of its outst
ing equity to Amedisys Inc., a publicly-held hospice company.
Represented a biomedical marketing company in its negotiations of various contracts with major pharmaceutical companies.
Represented a leading pharmacy provider to long-term care
post-acute care facilities in the acquisition of long-term care pharmacies located throughout the United States.
Represented a leading pharmacy provider in various operational
corporate governance matters.
Represented a pharmaceutical company developing injectable products for the treatment of allergic reactions in its acquisition by a developer of specialty pharmaceutical products.
Represented a biomedical device start-up company in the negotiation of a term credit facility.
Represented a biomedical device start-up company in the raise of Series B funding.
Represented a clinical stage biopharmaceutical company in the negotiation of clinical trial agreements with multiple research
educational institutions.
Represented leading medical cannabis operator in complicated opportunity zone investment opportunity, including fund raising, corporate governance matters,
real estate acquisition.
Represented a clinical-trial stage U.S.-based developer of medical devices in its sale to a publicly-traded, global health technology company.
General Mergers
Acquisitions: Represented DuPont (NYSE: DD), a global innovation leader with technology-based materials, in its $110 million acquisition of Evoqua's Memcor business, which includes ultrafiltration
membrane bio-filtration technologies.
Represented Pennsylvania Machine Works LLC, a leading manufacturer in the forged pressure fitting industry, in connection with the multimillion-dollar sale of all of its outst
ing equity to Wynnchurch Capital Partners.
Represented financial technology company in a minority investment transaction involving complex structure
resolution of minority-shareholder issues.
Represented a leading global financial institution in its investment in a leading fast-casual restaurant chain.
Gaming Transactions: Represented fubo Gaming Inc. f/k/a Vigtory, Inc., in entering into three sports wagering market access agreements: one in Indiana with Caesars Entertainment, one in New Jersey, also with Caesars Entertainment,
one in Iowa with Casino Queen.
Represented a leading sports betting media group,
a developer of educational platforms within the iGaming industry, in an affiliate agreement review.
Represented an online sports gaming entity in its acquisition of a multi-year operating license in Colorado.
Pro Bono: Regularly represents the national non-profit veterans organization, Folds of Honor, in its formation of local chapters.
Represented Emily's Entourage, a non-profit organization focused on rare mutations of cystic fibrosis, in their partnership with a leading clinical trial organization.
